

ACV1

Cat. No.:	HY-P1265
CAS No.:	740980-24-9
Molecular Formula:	C ₇₁ H ₁₀₃ N ₂₃ O ₂₅ S ₄
Molecular Weight:	1806.98
Sequence:	Met-Gly-Met-Arg-Met-Met-Phe-Thr-Val-Phe-Leu-Leu-Val-Val-Leu-Ala-Thr-Thr-Val-Val-Ser-Ser-Thr-Ser-Gly-Arg-Arg-Glu-Phe-Arg-Gly-Arg-Asn-Ala-Ala-Ala-Lys-Ala-Ser-Asp-Leu-Val-Ser-Leu-Thr-Asp-Lys-Lys-Arg-Gly-Cys-Cys-Ser-Asp-Pro-Arg-Cys-Asn-Tyr-Asp-His-Pro-Glu-Ile-Cys-Gly
Sequence Shortening:	MGMRRMMFTVLLVLATTWVSSSTSGRREFRGRNAAAKASDLVSLTDKKGCCSDPRCNYDHPE ICG
Target:	nAChR
Pathway:	Membrane Transporter/Ion Channel; Neuronal Signaling
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	ACV1 (Vc1.1), an α -Conotoxin, is a selective α 9 α 10 nAChR antagonist with an IC ₅₀ of 19 nM. ACV1 is ~100-fold less potent on human α 9 α 10 vs. rat nAChRs ^[1] .
IC ₅₀ & Target	IC50: 19 nM (α 9 α 10 nAChR), 140 nM (α 6/ α 3 β 2 β 3), 980 nM (α 6/ α 3 β 4) ^[1]

REFERENCES

[1]. J Michael McIntosh, et al. Alpha9 nicotinic acetylcholine receptors and the treatment of pain. Biochem Pharmacol. 2009 Oct 1;78(7):693-702.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA